3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
55
Neoplasm Metastasis
3
Stage II Prostate Adenocarcinoma
1
Sleep Initiation and Maintenance Disorders
1
Salivary Gland Neoplasms
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-Resistant Prostate Cancer
1
Metastatic Castrate-sensitive Prostate Cancer
1
Low Risk Prostate Cancer
1
Fatigue
1
Depression
1
Castration Levels of Testosterone
1
Adenocarcinoma
1
Interventions
enzalutamide
2
Docetaxel
2
Androgen Antagonists
2
darolutamide
1
apalutamide
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Hormone-sensitive Prostate Cancer
×
apalutamide
×
1 year
×
Clear all
NCT05901649
2026-06-05
ArtemisPRO
Janssen-Cilag Ltd.
Active not recruiting
504 enrolled